Publications by authors named "M Hongsuwan"
Background: Uncertainty over the therapeutic benefit of parenteral remdesivir in coronavirus disease 2019 (COVID-19) has resulted in varying treatment guidelines.
Methods: In a multicenter open-label, controlled, adaptive, pharmacometric platform trial, low-risk adult patients with early symptomatic COVID-19 were randomized to 1 of 8 treatment arms including intravenous remdesivir (200 mg followed by 100 mg daily for 5 days) or no study drug. The primary outcome was the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance (estimated under a linear model fit to the daily log10 viral densities, days 0-7) in standardized duplicate oropharyngeal swab eluates, in a modified intention-to-treat population.
Article Synopsis
- Delays in administering effective antibiotics for bacteremia can negatively impact patient survival rates.
- The study analyzed data from a Thai hospital and found that while patients with treatment delays of 3 or more days initially showed lower mortality rates than those with 1-2 days of delays, this was influenced by biases in the data.
- After adjusting for these biases, it was determined that delays in appropriate treatment were linked to a significant increase in 30-day mortality, suggesting prompt antibiotic treatment is critical for improving patient outcomes.
Background: Multi-modal interventions are effective in increasing hand hygiene (HH) compliance among healthcare workers, but it is not known whether such interventions are cost-effective outside high-income countries.
Aim: To evaluate the cost-effectiveness of multi-modal hospital interventions to improve HH compliance in a middle-income country.
Methods: Using a conservative approach, a model was developed to determine whether reductions in meticillin-resistant Staphylococcus aureus bloodstream infections (MRSA-BSIs) alone would make HH interventions cost-effective in intensive care units (ICUs).
Melioidosis in Thailand: Present and Future.
Trop Med Infect Dis
April 2018
A recent modelling study estimated that there are 2800 deaths due to melioidosis in Thailand yearly. The Thailand Melioidosis Network (formed in 2012) has been working closely with the Ministry of Public Health (MoPH) to investigate and reduce the burden of this disease. Based on updated data, the incidence of melioidosis is still high in Northeast Thailand.
View Article and Find Full Text PDFArticle Synopsis
- - The study analyzed data from nine public hospitals in northeast Thailand between 2004 and 2010 to assess the impact of multidrug-resistant (MDR) bacterial infections on mortality rates.
- - The 30-day mortality rates for different types of bacteraemia were found to be significantly high: 35% for community-acquired, 49% for healthcare-associated, and 53% for hospital-acquired infections.
- - In 2010, it was estimated that around 43% of deaths from hospital-acquired infections in Thailand were excess mortality related to MDR bacteria, indicating a severe public health issue likely seen in other low- and middle-income countries.